Literature DB >> 3256109

Studies on canine leishmaniasis control. 2. Effectiveness of control measures against canine leishmaniasis in the Isle of Elba, Italy.

L Gradoni1, M Gramiccia, F Mancianti, S Pieri.   

Abstract

A serological and parasitological survey carried out in 1985 in the Isle of Elba, Italy, revealed a high prevalence of canine leishmaniasis. This focus was considered ideal for the evaluation of effectiveness of treating infected dogs with meglumine antimoniate, applied as a control measure during 1985 and 1986. New data on prevalence were obtained for the years 1986 and 1987. Incidence of new canine leishmaniasis cases after the transmission seasons 1984, 1985 and 1986 were determined by examining 2 cohorts: cohort I, dogs born within 2 transmission seasons, and cohort II, adult dogs examined and found to be negative before each transmission season. Over 2000 tests were carried out on 1500 dogs. Prevalence analysis showed a reduction of infective dogs (symptomatic and oligosymptomatic) from 14.4% in 1985 to 5.2% in 1987. Incidence analysis showed a decrease of new cases from 12.4% after transmission season 1984 to 4.6% after transmission season 1987. The results indicate a two-thirds reduction of the disease frequency in dogs of the Isle of Elba after a 2-year period of control measures.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3256109     DOI: 10.1016/0035-9203(88)90511-1

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN: 0035-9203            Impact factor:   2.184


  8 in total

1.  The use of spatial analysis to estimate the prevalence of canine leishmaniasis in Greece and Cyprus to predict its future variation and relate it to human disease.

Authors:  Dimitra Sifaki-Pistola; Pantelis Ntais; Vasiliki Christodoulou; Apostolos Mazeris; Maria Antoniou
Journal:  Am J Trop Med Hyg       Date:  2014-06-23       Impact factor: 2.345

2.  Incidence and time course of Leishmania infantum infections examined by parasitological, serologic, and nested-PCR techniques in a cohort of naive dogs exposed to three consecutive transmission seasons.

Authors:  Gaetano Oliva; Aldo Scalone; Valentina Foglia Manzillo; Marina Gramiccia; Annalisa Pagano; Trentina Di Muccio; Luigi Gradoni
Journal:  J Clin Microbiol       Date:  2006-04       Impact factor: 5.948

3.  Susceptibility to visceral leishmaniasis in the domestic dog is associated with MHC class II polymorphism.

Authors:  Rupert J Quinnell; Lorna J Kennedy; Annette Barnes; Orin Courtenay; Christopher Dye; Lourdes M Garcez; Marie-Anne Shaw; Stuart D Carter; Wendy Thomson; William E R Ollier
Journal:  Immunogenetics       Date:  2003-03-20       Impact factor: 2.846

4.  Evora district as a new focus for canine leishmaniasis in Portugal.

Authors:  S J Semião-Santos; A el Harith; E Ferreira; C A Pires; C Sousa; R Gusmão
Journal:  Parasitol Res       Date:  1995       Impact factor: 2.289

5.  Methods of Control of the Leishmania infantum Dog Reservoir: State of the Art.

Authors:  Michele Podaliri Vulpiani; Luigi Iannetti; Daniela Paganico; Filomena Iannino; Nicola Ferri
Journal:  Vet Med Int       Date:  2011-07-07

6.  Double-Blind Randomized Efficacy Field Trial of Alum Precipitated Autoclaved Leishmania major (Alum-ALM) Vaccine Mixed With BCG Plus Imiquimod Vs. Placebo Control Group.

Authors:  Mohammad Barati; Mehdi Mohebali; Mohammad Hossein Alimohammadian; Ali Khmesipour; Hossein Keshavarz; Behnaz Akhoundi; Zabihollah Zarei
Journal:  Iran J Parasitol       Date:  2015 Jul-Sep       Impact factor: 1.012

7.  Use of miltefosine to treat canine visceral leishmaniasis caused by Leishmania infantum in Brazil.

Authors:  Fabio Dos Santos Nogueira; Valdir Carlos Avino; Fredy Galvis-Ovallos; Vera Lucia Pereira-Chioccola; Marcio Antonio Batistella Moreira; Ana Paula Peres Lopes Romariz; Leticia M Molla; Ingrid Menz
Journal:  Parasit Vectors       Date:  2019-02-08       Impact factor: 3.876

8.  Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis.

Authors:  J Moreno; J Nieto; S Masina; C Cañavate; I Cruz; C Chicharro; E Carrillo; S Napp; C Reymond; P M Kaye; D F Smith; N Fasel; J Alvar
Journal:  Vaccine       Date:  2007-06-04       Impact factor: 3.641

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.